Current Diabetes Reports

, Volume 4, Issue 6, pp 462–469

Gene expression in diabetic nephropathy

  • Daniela Hohenadel
  • Fokko J. van der Woude
Article

Abstract

Diabetic nephropathy (DN) is a common complication of diabetes types 1 and 2. One of the hallmarks of DN is the development of mesangial expansion, which occurs through accumulation of extracellular matrix (ECM) components. Altered local gene expression of humoral factors (eg, transforming growth factor-â, connective tissue growth factor, and platelet-derived growth factor) can lead to increased production of ECM components (eg, fibronectin and collagen IV) or decreased degradation through matrix metal oproteinases (eg, MMP-1, MMP-2). In recent years, new techniques for examination of gene expression have been developed. Because of their large scale and high-throughput character, it is now possible to examine differential gene expression in a large number of samples. This paper provides an overview of techniques used and results obtained in studies of DN. Newly developed concepts of how altered gene expression may affect histomorphologic features or clinical symptoms are also discussed.

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References and Recommended Reading

  1. 1.
    U.S. Renal Data System, USRDS 2003 Annual Data Report: Atlas of End-Stage Renal Disease in the United States. Bethesda, MD: National Institutes of Health, National Institute of Diabetes and Digestive and Kidney Diseases; 2003.Google Scholar
  2. 2.
    Intensive blood glucose control with sulphonylureas or insulin compared to conventional treatment and the risk of complications in patients with type 2 diabetes. UK Prospective Diabetes Study Group (UKPDS) [no authors listed]. Lancet 1998, 352:837–853.Google Scholar
  3. 3.
    The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulintreated diabetes mellitus. The Diabetes Control and Complications Trial Research Group [no authors listed]. N Engl J Med 1993, 329:977–986.Google Scholar
  4. 4.
    Seaquist ER, Goetz FC, Rich S, Barbosa J: Familial clustering of diabetic kidney disease. Evidence for genetic susceptibility to diabetic nephropathy. N Engl J Med 1989, 320:1161–1165.PubMedCrossRefGoogle Scholar
  5. 5.
    Ziyadeh FN: The extracellular matrix in diabetic nephropathy. Am J Kidney Dis 1993, 22:736–744.PubMedGoogle Scholar
  6. 6.
    Fryer RM, Randall J, Yoshida T, et al.: Global analysis of gene expression: methods, interpretation, and pitfalls. Exp Nephrol 2002, 10:64–74.PubMedCrossRefGoogle Scholar
  7. 7.
    Eikmans M, Baelde HJ, de Heer E, Bruijn JA: RNA expression profiling as prognostic tool in renal patients: toward nephrogenomics. Kidney Int 2002, 62:1125–1135.PubMedCrossRefGoogle Scholar
  8. 8.
    Murphy M, Godson C, Cannon S, et al.: Suppression subtractive hybridization identifies high glucose levels as a stimulus for expression of connective tissue growth factor and other genes in human mesangial cells. J Biol Chem 1999, 274:5830–5834.PubMedCrossRefGoogle Scholar
  9. 9.
    Gygi SP, Rochon Y, Franza BR, Aebersold R: Correlation between protein and mRNA abundance in yeast. Mol Cell Biol 1999, 19:1720–1730.PubMedGoogle Scholar
  10. 10.
    Holmes DIR, Wahab NA, Mason RM: Identification of glucoseregulated genes in human mesangial cells by mRNA differential display. Biochem Biophys Res Comm 1997, 238:179–184.PubMedCrossRefGoogle Scholar
  11. 11.
    Holmes DIR, Wahab NA, Mason RM: Cloning and characterization of ZNF236, a glucose-regulated Kruppel-like zinc-finger gene mapping to human chromosome 18q22-q23. Genomics 1999, 60:105–109.PubMedCrossRefGoogle Scholar
  12. 12.
    Vardarli I, Baier LJ, Hanson RL, et al.: Gene for susceptibility to diabetic nephropathy in type 2 diabetes maps to 18q22.3-23. Kidney Int 2002, 62:2176–2183.PubMedCrossRefGoogle Scholar
  13. 13.
    Halama N, Yard-Breedijk A, Vardarli I, et al.: The Kruppel-like zinc-finger gene ZNF236 is alternatively spliced and excluded as susceptibility gene for diabetic nephropathy. Genomics 2003, 83:406–411.CrossRefGoogle Scholar
  14. 14.
    Susztak K, Böttinger E, Novetsky A, et al.: Molecular profiling of diabetic mouse kidney reveals novel genes linked to glomerular disease. Diabetes 2004, 53:784–794. The approach to molecular profiling of the diabetic mouse kidney and its link to human diabetic nephropathy is excellently described.PubMedCrossRefGoogle Scholar
  15. 15.
    Junaid A, Amara FM: Osteopontin: correlation with interstitial fibrosis in human diabetic kidney and PI3-kinase-mediated enhancement of expression by glucose in human proximal tubular epithelial cells. Histopathology 2004, 44:136–146.PubMedCrossRefGoogle Scholar
  16. 16.
    Morrison J, Knoll K, Hessner MJ, Liang M: Effect of high glucose on gene expression in mesangial cells: upregulation of the thiol pathway is an adaptational response. Physiol Genomics 2004, 17:271–282.PubMedCrossRefGoogle Scholar
  17. 17.
    Fan Q, Shike T, Shigihara T, et al.: Gene expression profile in diabetic KK/Ta mice. Kidney Int 2003, 64:1978–1985.PubMedCrossRefGoogle Scholar
  18. 18.
    Baelde HJ, Eikmans M, Doran PP, et al.: Gene expression profiling in glomeruli from human kidneys with diabetic nephropathy. Am J Kidney Dis 2004, 43:636–650. The first study to examine global gene expression in human diabetic nephropathy.PubMedCrossRefGoogle Scholar
  19. 19.
    McMahon R, Murphy M, Clarkson M, et al.: IHG-2, a mesangial cell gene induced by high glucose, is human gremlin. J Biol Chem 2000, 275:9901–9904.PubMedCrossRefGoogle Scholar
  20. 20.
    Lappin DWP, McMahon R, Murphy M, Brady HR: Gremlin: an example of the re-emergence of developmental programmes in diabetic nephropathy. Nephrol Dial Transplant 2002, 17(suppl 9):65–67.PubMedCrossRefGoogle Scholar
  21. 21.
    Ayo SH, Radnik RA, Garoni JA, et al.: High glucose causes an increase in extracellular matrix proteins in cultured mesangial cells. Am J Pathol 1990, 136:1339–1348.PubMedGoogle Scholar
  22. 22.
    Border WA, Noble NA: Transforming growth factor beta in tissue fibrosis. N Engl J Med 1994, 331:1286–1292.PubMedCrossRefGoogle Scholar
  23. 23.
    Chen S, Jim B, Ziyadeh FN: Diabetic nephropathy and transforming growth factor-beta: transforming our view of glomerulosclerosis and fibrosis build-up. Semin Nephrol 2003, 23:532–543. Gives an excellent overview of known facts about TGF-â, its expression, functional relevance, and pathologic changes in DN.PubMedCrossRefGoogle Scholar
  24. 24.
    Lam S, Verhagen NA, Strutz F, et al.: Glucose-induced fibronectin and collagen type III expression in renal fibroblasts can occur independent of TGFbeta1. Kidney Int 2003, 63:878–888.PubMedCrossRefGoogle Scholar
  25. 25.
    Adler SG, Kang S, Feld S, et al.: Glomerular mRNAs in human type 1 diabetes: biochemical evidence for microalbuminuria as a manifestation of diabetic nephropathy. Kidney Int 2001, 60:2330–2336.PubMedCrossRefGoogle Scholar
  26. 26.
    Perkins BA, Fiocciello LH, Silva KH, et al.: Regression of microalbuminuria in type 1 diabetes. N Engl J Med 2003, 348:2285–2293.PubMedCrossRefGoogle Scholar
  27. 27.
    Lam S, van der Geest RN, Verhagen NA, et al.: Secretion of collagen type IV by human renal fibroblasts is increased by high glucose via a TGF-beta-independent pathway. Nephrol Dial Transplant 2004, 19:1694–1701.PubMedCrossRefGoogle Scholar
  28. 28.
    Mogyorosi A, Ziyadeh FN: GLUT1 and TGFbeta: the link between hyperglycemia and diabetic nephropathy. Nephrol Dial Transplant 1999, 14:2827–2829.PubMedCrossRefGoogle Scholar
  29. 29.
    Weigert C, Brodbeck K, Brosius FC, et al.: Evidence for a novel TGFbeta-independent mechanism of fibronectin production in mesangial cells overexpressing glucose transporters. Diabetes 2003, 52:527–535.PubMedCrossRefGoogle Scholar
  30. 30.
    Riser BL, Denichilo M, Cortes P, et al.: Regulation of connective tissue growth factor activity in cultured rat mesangial cells and its expression in experimental diabetic glomerulosclerosis. J Am Soc Nephrol 2000, 11:25–28.PubMedCrossRefGoogle Scholar
  31. 31.
    Ito Y, Aten J, Bende RJ, et al.: Expression of connective tissue growth factor in human renal fibrosis. Kidney Int 1998, 53:853–861.PubMedCrossRefGoogle Scholar
  32. 32.
    Wahab NA, Yevdokimova N, Weston BS, et al.: Role of connective tissue growth factor in the pathogenesis of diabetic nephropathy. Biochem J 2001, 359:77–87.PubMedCrossRefGoogle Scholar
  33. 33.
    Schrijvers BF, Flyvbjerg A, De Vriese AS: The role of vascular endothelial growth factor (VEGF) in renal pathophysiology. Kidney Int 2004, 65:2003–2017. Review of VEGF and its role in different renal diseases, including a thorough review of VEGF regulation in type 1 and 2 diabetes. Results of human, experimental, and cell culture experiments are discussed.PubMedCrossRefGoogle Scholar
  34. 34.
    Langham RG, Kelly DJ, Maguire J, et al.: Over-expression of platelet-derived growth factor in human diabetic nephropathy. Nephrol Dial Transplant 2003, 18:1392–1396.PubMedCrossRefGoogle Scholar
  35. 35.
    Kelly DJ, Gilbert RE, Cox AJ, et al.: Aminoguanidine ameliorates overexpression of prosclerotic growth factors and collagen deposition in experimental diabetic nephropathy. J Am Soc Nephrol 2001, 12:2098–2107.PubMedGoogle Scholar
  36. 36.
    Langham RG, Kelly DJ, Cox AJ, et al.: Proteinuria and the expression of the podocyte slit diaphragm protein, nephrin, in diabetic nephropathy: effects of angiotensin converting enzyme inhibition. Diabetologia 2002, 45:1572–1576.PubMedCrossRefGoogle Scholar
  37. 37.
    Toyoda M, Suzuki D, Umezono T, et al.: Expression of human nephrin mRNA in diabetic nephropathy. Nephrol Dial Transplant 2004, 19:380–385.PubMedCrossRefGoogle Scholar
  38. 38.
    Benigni A, Gagliardini E, Tomasoni S, et al.: Selective impairment of gene expression and assembly of nephrin in human diabetic nephropathy. Kidney Int 2004, 65:2193–2200.PubMedCrossRefGoogle Scholar
  39. 39.
    Doublier S, Salvidio G, Lupia E, et al.: Nephrin expression is reduced in human diabetic nephropathy: evidence for a distinct role for glycated albumin and angiotensin II. Diabetes 2003, 52:1023–1030.PubMedCrossRefGoogle Scholar
  40. 40.
    Kelly DJ, Aaltonen P, Cox AJ, et al.: Expression of the slitdiaphragm protein, nephrin, in experimental diabetic nephropathy: differing effects of anti-proteinuric therapies. Nephrol Dial Transplant 2002, 17:1327–1332.PubMedCrossRefGoogle Scholar
  41. 41.
    Aaltonen P, Luimula P, Åstöm E, et al.: Changes in the expression of nephrin gene and protein in experimental diabetic nephropathy. Lab Invest 2001, 81:1185–1190.PubMedCrossRefGoogle Scholar
  42. 42.
    Awazu M, Omori S, Ishikura K, et al.: The lack of cyclin kinase inhibitor p27Kip1 ameliorates progression of diabetic nephropathy. J Am Soc Nephrol 2003, 14:699–708.PubMedCrossRefGoogle Scholar
  43. 43.
    Yard BA, Kahlert S, Engelleiter R, et al.: Decreased glomerular expression of agrin in diabetic nephropathy and podocytes, cultured in high glucose medium. Exp Nephrol 2001, 9:214–222.PubMedCrossRefGoogle Scholar
  44. 44.
    Brinkkoetter PT, Holtgrefe S, van der Woude FJ, Yard BA: Angiotensin II type 1-receptor mediated changes in heparan sulfate proteoglycans in human SV40 transformed podocytes. J Am Soc Nephrol 2004, 15:33–40.PubMedCrossRefGoogle Scholar
  45. 45.
    Wang SN, Lapage J, Hirschberg R: Loss of tubular bone morphogenetic protein-7 in diabetic nephropathy. J Am Soc Nephrol 2001, 12:2392–2399.PubMedGoogle Scholar
  46. 46.
    Wang S, Chen Q, Simon TC, et al.: Bone morphogenic protein-7 (BMP7), a novel therapy for diabetic nephropathy. Kidney Int 2003, 63:2037–2049.PubMedCrossRefGoogle Scholar
  47. 47.
    McLennan SV, Yue DK, Turtle JR: Effect of glucose on matrix metalloproteinase activity in mesangial cells. Nephron 1998, 79:293–298.PubMedCrossRefGoogle Scholar
  48. 48.
    Fornoni A, Striker LJ, Zheng F, Striker GE: Reversibility of glucoseinduced changes in mesangial cell extracellular matrix depends on the genetic background. Diabetes 2002, 51:499–505.PubMedCrossRefGoogle Scholar
  49. 49.
    Mc Lennan SV, Martell SKY, Yue DK: Effects of mesangium glycation on matrix metalloproteinase activities: possible role in diabetic nephropathy. Diabetes 2002, 51:2612–2618.CrossRefGoogle Scholar
  50. 50.
    Del Prete D, Anglani F, Forino M, et al.: Down-regulation of glomerular matrix metalloproteinase-2 gene in human NIDDM. Diabetologia 1997, 40:1449–1454.PubMedCrossRefGoogle Scholar

Copyright information

© Current Science Inc 2004

Authors and Affiliations

  • Daniela Hohenadel
    • 1
  • Fokko J. van der Woude
    • 1
  1. 1.Fifth Medical DepartmentUniversity Clinic MannheimMannheimGermany

Personalised recommendations